Argenx to elevate Massey to CEO as it expands rare disease business

CellPrion-based protein self-assembly tunes mutagenesis to enable rapid adaptation

Endpoints NewsEthyreal lands $101M to treat both Graves' and thyroid eye disease

Endpoints NewsSanofi to mull riliprubart’s future after stopping late-stage nerve disease study

FierceBiotechCancer-focused Parabilis’ upsized $670M IPO breaks new for record for biotechs

FierceBiotechSanofi halts phase 3 autoimmune trial early over insufficient efficacy as pipeline woes continue

LabiotechBeyond amyloid and dopamine: emerging technologies reshaping neurology

Endpoints NewsParabilis' $670M IPO sets new biotech record, will fund cancer drug

eLifeAltered cognitive processes shape tactile perception in autism

eLifeCell size modulates ferroptosis susceptibility

Clinical OMICsExposure to Moderate Air Pollution Raises Cardiovascular Disease Risk

Endpoints NewsEli Lilly's claims data deadline may kick off new 340B fight

Clinical OMICsFirst Phase III for Resected CRC ctDNA-Guided Therapy Shows Mixed Results